The EU's Falsified Medicines Directive and APIs - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The EU's Falsified Medicines Directive and APIs
Siegfried Schmitt, a principal consultant with PAREXEL, discusses how the EU's Falsified Medicines Directive will affect US API production.

Pharmaceutical Technology
Volume 37, Issue 2

Q. Assuming FDA will not take any action, what does this mean for APIs originating in the US for import into the EU after July 1, 2013?

A. These APIs will be illegal and cannot be placed on the market. Given the extremely short timeline, this has already caused some NCAs, such as the United Kingdom's MHRA, to publicly voice concerns over drug-supply shortages as a result of this legislation. Of course, the EU agencies could go and inspect API manufacturers in non-EU countries, something that is happening already. The problem is the sheer number of these manufacturing sites and the limited resources for inspection. It simply isn't an option for most sites.

Q. Are there options for transitional solutions?

A. The EC has remained adamant that the law (i.e., the directive) cannot be changed and must be enforced. Nonetheless, there are many diplomatic missions underway to assure a continued drug supply in Europe. But, some companies have already taken steps to move their drug product manufacture out of Europe.

And do not forget that this directive affects not just the manufacturers, but all involved in the import and handling of the APIs, such as importers, wholesalers, and brokers. They must comply with good distribution practices (GDP) and may be inspected. It is not helpful that the new EU GDP guidelines are only expected for publication in early 2013. This leaves very little time for industry to become compliant.

Q. What do you think industry should do?

A. Industry associations are already working very hard and in collaboration with the EU authorities to gain as much clarity on what needs to be done and how. Engaging with industry associations or non-profit organizations such as the International Society for Pharmaceutical Engineers (ISPE) and the Parenteral Drug Association (PDA), next to carefully watching information coming from the agencies are the best sources of information. Unfortunately, there is very little that industry can do, but a lot that must be done by a number of agencies. At the moment, the verdict as to whether this directive proves to benefit the patients or brings about drug shortages is wide open.

More information on the organizations mentioned in this article can be found at their respective websites:


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here